Hejing Bao on Muck Rack

Hejing Bao

As seen in: Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hejing

Contact Hejing, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Case Report: A successful rechallenge with aumolertinib after osimertinib-induced severe interstitial lung disease

|
By Caijiu Deng, XI LUO, Haoran Su, Xiaolong Cao, Liping Lin, Hejing Bao, Hehong Bao, Jiazhu Hu
| Frontiers
Abstract Background: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), demonstrates significant efficacy in treating non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutations. However, EGFR-TKI-induced interstitial lung disease (ILD) is a recognized and severe adverse reaction that can be fatal.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified